Chiesi buys into Arbor gene editing drug for rare kidney disease

The Italian drugmaker will pay as much as $115 million in upfront and near-term payments in a deal that gives it rights to a treatment in early-stage testing for primary hyperoxaluria type 1.

Peter Marks, former top FDA vaccine official, joins Eli Lilly

Six months after his abrupt resignation as CBER director, Marks has been hired to run discovery and infectious disease work at the big Indianapolis drugmaker.

Unlocking the potential of AI in pharma

The top biopharma conferences in 2026

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.

FDA clears generic abortion pill; CMS punts ‘combo drug’ guidance

The decision to clear another mifepristone generic sparked political backlash. Elsewhere, investors will pump up to $175 million into Ovid after the company reported early, but encouraging, data for a potential epilepsy drug.

Biotech startups are built on venture capital. Track funding rounds here.

Expedition Therapeutics, a startup aiming to in-license drugs from China, raised $165 million in the third nine-figure Series A round announced in the last three days.

Soufflé Therapeutics Gets Venture, Pharma Backing for Genetic Medicines

‘CRISPR cure’ headlines disappoint rare disease parents

Baby Steps: Kiran Musunuru Lays Out the Path Beyond KJ at ESGCT